Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lynsey Shaffer"'
Autor:
Charles W. Wright, Naomi Li, Lynsey Shaffer, Armetta Hill, Nicolas Boyer, Stephen E. Alves, Sriraman Venkataraman, Kaustav Biswas, Linda A. Lieberman, Sina Mohammadi
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Disruptions in the gut epithelial barrier can lead to the development of chronic indications such as inflammatory bowel disease (IBD). Historically, barrier function has been assessed in cancer cell lines, which do not contain all human inte
Externí odkaz:
https://doaj.org/article/53dd0fbf350741229b237e3cc1522057
Autor:
Charles W. Wright, Naomi Li, Lynsey Shaffer, Armetta Hill, Nicolas Boyer, Stephen Alves, Sriram Venkat, Kaustav Biswas, Linda A. Lieberman, Sina Mohammadi
Disruptions in the gut epithelial barrier can lead to the development of chronic indications such as inflammatory bowel disease (IBD). Historically, barrier function has been assessed in cancer cell lines, which do not contain all human intestinal ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a5c487ef12d61187d57398773a1b32a
https://doi.org/10.1101/2022.12.16.520780
https://doi.org/10.1101/2022.12.16.520780
Autor:
Joey L. Methot, Hua Zhou, Sam D. Kattar, Meredeth A. McGowan, Kevin Wilson, Yudith Garcia, Yongi Deng, Michael Altman, Xavier Fradera, Charles Lesburg, Thierry Fischmann, Chaomin Li, Steve Alves, Sanjiv Shah, Rafael Fernandez, Peter Goldenblatt, Armetta Hill, Lynsey Shaffer, Dapeng Chen, Vince Tong, Robbie L. McLeod, Hongshi Yu, Alan Bass, Ray Kemper, Nicholas T. Gatto, Lisa LaFranco-Scheuch, Benjamin Wesley Trotter, Timothy Guzi, Jason D. Katz
Publikováno v:
Journal of Medicinal Chemistry. 62:4370-4382
PI3Kδ catalytic activity is required for immune cell activation, and has been implicated in inflammatory diseases as well as hematological malignancies in which the AKT pathway is overactive. A purine PI3Kδ inhibitor bearing a benzimidazolone-piper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22455e06a228a36e7b0e36ea97794591
https://doi.org/10.1021/acs.jmedchem.8b01818
https://doi.org/10.1021/acs.jmedchem.8b01818
Autor:
Benjamin Wesley Trotter, Xavier Fradera, Stephen E. Alves, Meredeth A. McGowan, Peter Goldenblatt, Jason D. Katz, Yudith Garcia, Lynsey Shaffer, Michael D. Altman, Matthew Christopher, Kathryn Lipford, Charles A. Lesburg, Hyun-Hee Lee, Chaomin Li, Craig P. Chappell, Vincent Tong, Elaine M. Pinheiro, Armetta D. Hill, Ruban Mangado, Renu Jain, Robbie L. McLeod, Sanjiv J. Shah, Hongshi Yu, Abdelghani Achab, Dapeng Chen, Joey L. Methot, Sybill M G Williams, Hua Zhou, Neville J. Anthony
Publikováno v:
Journal of medicinal chemistry. 64(8)
The approvals of idelalisib and duvelisib have validated PI3Kδ inhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a62dfaa61d20ec22ebc7d156d70d73
https://pubmed.ncbi.nlm.nih.gov/33797901
https://pubmed.ncbi.nlm.nih.gov/33797901
Autor:
Michael D. Altman, Jason D. Katz, Hua Zhou, Joey L. Methot, Vincent Tong, Kevin J. Wilson, Yudith Garcia, Peter Goldenblatt, Abdelganhi Achab, Martin Augustin, Charles A. Lesburg, Qiaolin Deng, Solomon Kattar, Lynsey Shaffer, Xavier Fradera, Meredeth A. McGowan, Sanjiv J. Shah
Publikováno v:
Bioorganicmedicinal chemistry letters. 42
PI3K-δ mediates key immune cell signaling pathways and is a target of interest for treatment of oncological and immunological disorders. Here we describe the discovery and optimization of a novel series of PI3K-δ selective inhibitors. We first iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f9bff15a42c345e0eae2a3ff5da3cf0
https://pubmed.ncbi.nlm.nih.gov/33865969
https://pubmed.ncbi.nlm.nih.gov/33865969
Autor:
Kevin W. Johnson, Peter Fuller, Sujal V. Deshmukh, Fang He, Peter Goldenblatt, Lauren Dorosh, Hongbo Zeng, Jason D. Brubaker, Luis E. Torres, Tony Siu, Fiona Elwood, Charles A. Lesburg, Sangita B. Patel, Duan Liu, Elma Kadic, Christopher J. Dinsmore, Xavier Fradera, Lynsey Shaffer, Jonathan R. Young, Lily Y. Moy, Feng Shi, Carla Alpert, Joel A. Klappenbach, Joshua Close, Rafael Fernandez, Hongshi Yu, Nathan Bays, Dawn M. Mampreian
Publikováno v:
Journal of Medicinal Chemistry. 60:9676-9690
The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemistry strategy focused on optimization of key paramete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6959a9f84f358dff1679660f1f0b87e
https://doi.org/10.1021/acs.jmedchem.7b01135
https://doi.org/10.1021/acs.jmedchem.7b01135
Autor:
Chaomin Li, Charles A. Lesburg, Jason D. Katz, Xavier Fradera, Robbie L. McLeod, Ruban Mangado, Elaine M. Pinheiro, Sybil M. G. Williams, Benjamin Wesley Trotter, Craig P. Chappell, Stephen E. Alves, Armetta D. Hill, Sanjiv J. Shah, Lynsey Shaffer, Michael D. Altman, Joey L. Methot, Hua Zhou, Renu Jain, Dapeng Chen, Hyun-Hee Lee, Meredith A. McGowan, Peter Goldenblatt
Publikováno v:
Cancer Research. 79:2254-2254
Inhibitors of PI3Kdelta are approved as monotherapy for the treatment of hematologic malignancies such as follicular B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Recent reports suggest that inhibition of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01203c857b786686ef70cf3c512ad5f8
https://doi.org/10.1158/1538-7445.am2019-2254
https://doi.org/10.1158/1538-7445.am2019-2254